The Unsung Hero of Drug Discovery Kinetics

It's no secret that pharma companies are struggling to protect themselves from cyberattacks amid the pandemic. Data breaches are costing the sector around US$5m a year, while one in 10 pharma companies are at risk of a ransomware attack, exacerbated by a perfect storm of shifting to remote working, increased growth, antiquated OT systems and a lack of cybersecurity skills.

Characterization of residual impurities for gene therapy drug products is particularly challenging due to the complex nature of the final products as well as the complicated processes required to manufacture them.

Typically, Manufacturing Operations and Support Personnel spend too much time trying to navigate a complex information landscape to locate data, extract it and combine it with data from other systems to gain insights about the assets and drug manufacturing processes they support and service. At Eli Lilly, as a part of their Digital Plant journey, a program called “DaVinci” (among many others) was created to address this problem head-on. DaVinci is a comprehensive data integration platform with embedded data visualization, analytics, and knowledge sharing capability that also provides the flexibility for users to bring their own data and tools to the platform via “plug and play” functionality. It also provides a shared workbench to conduct quick analytics on near-real-time data to gain timely insights on manufacturing processes.

Find out which market-moving events and catalysts to watch for during the upcoming Q1 Outlook Webinar - Key catalysts and their impact on pharma markets. During this webinar recording, industry analysts from Informa Pharma Intelligence present their data-based views on what’s in store for key drugs in early 2019. Discussion include important upcoming events related to these key drugs, their likelihood of phase/PDUFA review success and likelihood of approval, and an examination of the market significance of the drugs themselves.